SYNTHOS RESEARCH

BXP BXP

Real Estate · REIT - Office · Synthos Deep Dive · 2026-07-03

$69.32
Hold
Risk 7Growth 3Exponential 2Fair value $70 $48–$88

At a glance

VerdictHold — systematic Synthos tier
Price (2026-07-02)$69.32 · market cap ~$11.1B
Synthos scores (0–10)Downside Risk 7 · Growth Quality 3 · Exponential Potential 2
Synthos fair value (base case)~$70~+1% · full range $48 (bear) – $88 (bull)
Street consensus$65.50 (high $72 / low $61; 24 Buy · 17 Hold · 1 Sell) — context, not our anchor
Valuation~9.9× FY26E FFO ($6.97 mid) · P/E 35× trailing (misleading for a REIT) · EV/EBITDA 14× · net-debt/EBITDA 8.2×
Dividend$2.80/yr, ~4.0% yield, ~40% of FFO — covered and a core part of the return
Exponential Potential2/10 · Very Low — mature, decelerating, single-asset-class office; no room-to-run optionality
TechnicalsRecovering — $69.32, above 50/200-DMA, RSI 62; but only +1.8% 12-mo (SPY +21%) and −48% max drawdown from peak
ConvictionLow — 0 expert voices in the KB; the call rests entirely on fundamentals + quant
Position sizingIncome/tactical only, ≤2% if held for the yield — not a core holding
Next catalyst2026-07-28 Q2'26 earnings (Street EPS $0.43; management FFO guide $1.69–$1.71)
Single biggest riskOffice secular demand + 8.2× leverage into a higher-for-longer rate world

One-line thesis. BXP owns the best Class-A office towers in five US gateway cities and trades at a cheap ~9.9× forward FFO with a covered 4% yield — but revenue has flatlined (~1%/yr), FFO is flat-to-down, and the balance sheet carries 8.2× net-debt/EBITDA into a structurally challenged office market; it is a cheap, high-yield income vehicle for those who want office exposure, not a compounder — hence Watch.

◆ Synthos call — Hold BXP is a solid business largely reflected at ~$70 — fine to keep, no reason to chase; it gets interesting again below ~$60.
Downside Risk (lower = safer)
7/10 · High
8.2× net-debt/EBITDA and a −48% peak drawdown dominate; cheap on FFO but leverage & office cyclicality are the risk.
Growth Quality
3/10 · Low
~1% revenue growth, flat-to-down FFO, thin 6% ROE — an income REIT, not a grower.
Exponential Potential
2/10 · Low
Mature, decelerating, single-asset-class office REIT; no room-to-run optionality — the opposite of exponential.
⚖ Reverse-DCF cross-check Market-implied growth ≈ -1%/yr To justify today’s $69, earnings would have to compound roughly -1% a year for 10 years (9% discount rate). Analysts forecast ~11%/yr, so the market is pricing in LESS than what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

BXP is a landlord. It builds and rents out top-tier office towers in five expensive cities — Boston, New York, San Francisco, Washington DC, and Los Angeles. It is set up as a REIT, which means it must pay out most of its profit to shareholders as a dividend; right now that dividend is about 4% a year, and the company earns enough to cover it.

Is the stock cheap or expensive? On the measure that matters for a landlord — cash rental profit per share (called "FFO") — it looks cheap: you pay under $10 for every $1 of yearly cash profit. But cheap is not the same as good. The rent it collects has basically stopped growing, and the company owes a lot of money — about eight years' worth of profit in debt — which is dangerous when interest rates stay high and offices sit half-empty in some cities.

Our verdict is Watch: not a buy, not a sell. It could be fine as a small income holding if you specifically want office-property exposure and the 4% dividend, but it is not a wealth-builder.

Here's what our three scores mean in everyday terms:

The one big worry: the world may permanently need less office space (remote/hybrid work), and BXP's large debt magnifies any pain if rents or property values fall.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

4957657381Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $79Price 69200-DMA 6550-DMA 6252w lo $51

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

4655657483Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26Price 6920-day avg 65

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 69.4

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 69.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26MACD 1.8signal 1.6

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLRE (sector)), set to 100 a year ago

718599112126Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26S&P 500 120XLRE (sector) 107BXP 102

Solid = BXP · dashed = S&P 500 · dotted = XLRE (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

01234$3BFY23EPS $1$3BFY24EPS $2$3BFY25EPS $1$3BFY26EEPS $2$4BFY27EEPS $2$4BFY28EEPS $2$4BFY29EEPS $2$4BFY30EEPS $0

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$69.32
Market cap$11B
P/E trailing
P/E FY26E / FY27E33× / 37×
EV / Sales7.6×
EV / EBITDA14.1×
Gross margin60.2%
Net margin9.1%
Dividend yield4.04%
Beta1.062
52-wk range$51 – $79
RSI(14)62
50 / 200-DMA$62 / $65
12-mo return+2% (SPY +21%)
Street target$66 ($61–$72)
Analyst grades24 Buy · 17 Hold · 1 Sell
FMP ratingB-
Next earnings2026-08-05

What the experts actually said 0 traceable claims on BXP · showing the highest-conviction voices

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

BXP, Inc. (NYSE: BXP), formerly Boston Properties, is the largest publicly traded owner/developer of premier Class-A office ("premier workplace") properties in the US, structured as a REIT. As of Q1'26 the portfolio totals ~50.4M square feet across 164 properties (including six under construction/redevelopment), concentrated in six gateway markets: Boston, Los Angeles, New York, San Francisco, Seattle, and Washington DC. It is externally the definition of a single-asset-class, gateway-city office landlord. Fiscal year ends December 31; CEO is Owen Thomas.

Revenue mix (FY2025, from FMP segmentation + filings):

The core economic engine is rent from long-term leases on trophy office assets. The strategic story management is telling (Investor Day, Sept 2025) is defensive: lease up the ~350-bps gap between leased and occupied space (~1.6M sq ft of signed-but-not-commenced leases), sell non-strategic assets (~$1.2B of proceeds to date) to de-lever, and let the flight-to-quality within office favor the best buildings.

2. The expert thesis — why the panel is bullish (traceable)

There is no expert coverage of BXP in the Synthos knowledge base. total_claims = 0; there are zero net-bullish and zero cautionary voices on file. None of the tracked high-skill investors we distill (the metabolic/AI/compounder-focused panel) have said anything traceable about an office REIT.

Accordingly, this note carries no expert-conviction weight and cites no claim_id values — because none exist. The verdict below is entirely fundamentals- and quant-driven, built from the FMP financials, analyst estimates, management's own SEC-filed guidance (§9), and our scoring framework. Where the Street has an opinion, we show it as context (24 Buy / 17 Hold / 1 Sell, consensus target $65.50), not as conviction. Absence of coverage is itself information: BXP is not a name the Synthos expert panel is leaning into.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)7 · ElevatedCheap on FFO (~9.9×) and beta ~1.06, but 8.2× net-debt/EBITDA, a −48% max drawdown from peak, and office cyclicality/secular demand risk dominate. Leverage is the story.
Growth Quality3 · WeakRevenue ~+1%/yr (FY24→FY25 +2.2%), FFO/share flat-to-down ($6.85 FY25 → $6.97 mid FY26E), ROE ~6%, ROIC ~5%. A durable income REIT, not a grower.
Exponential Potential2 · Very LowMature, decelerating, single-asset-class office landlord at $11B cap with no TAM-expansion optionality. The opposite of an accelerating multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. For a REIT the honest valuation lever is FFO/share × a price/FFO multiple, plus the ~4% dividend collected along the way.

CaseKey assumptionsFair value
BullOffice flight-to-quality accelerates; the ~1.6M sq ft signed-not-commenced backlog commences on schedule; asset sales de-lever toward ~7× and rates ease. FY27E FFO ~$7.30; multiple re-rates to ~12×.~$88 (+27%)
Base (our anchor)Guidance roughly holds — FY26 FFO ~$6.97 (mgmt mid), essentially flat FY27; a leveraged, low-growth office REIT earns ~10× FFO. Add the ~4% dividend.~$70 (~+1% price, ~+5% total)
BearOffice demand weakens again, SF/DC vacancy rises, refinancing at higher rates compresses FFO to ~$6.20, and the multiple de-rates to ~7.5× as leverage bites.~$48 (−31%)

Synthos fair value = the base case, ~$70 (roughly flat on price, ~+5% total return with the dividend), with the full $48–$88 span as the honest range. This anchor sits above the Street's $65.50 consensus because we credit the covered dividend and the de-levering asset-sale plan; our bear is meaningfully below the Street's $61 low because we take the leverage-plus-office-secular tail seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). BXP is neither — it is a mature, cyclical income REIT:

Exponential Potential: Very Low (2/10). Own BXP, if at all, for the ~4% yield and a cyclical office-recovery bet — never for exponential upside. This honest framing is why it cannot sit in a growth or "next-exponential" sleeve.

5. Financials (real numbers — FMP annual/quarterly)

Note: for a REIT, GAAP EPS and P/E are distorted by heavy depreciation; FFO (funds from operations) is the correct earnings proxy and is used throughout.

6. Valuation — priced in or room?

On the right REIT metric, BXP is statistically cheap: ~9.9× FY26E FFO ($6.97 mid) and EV/EBITDA ~14×, with a ~4.0% dividend yield covered ~2.5× by FFO. Price/book is ~2.1× and the stock trades at ~$69 vs a ~$79 52-week high. The bear counter is that cheap is deserved: 8.2× net-debt/EBITDA, ~1% growth, and office secular risk justify a low multiple, and a rate-driven refinancing squeeze could push FFO and the multiple down together (the bear case). Street targets (context): consensus $65.50, high $72, low $61 — the Street essentially sees BXP as fairly-to-fully valued here, and our ~$70 base is modestly more constructive on the strength of the covered dividend and the de-levering plan. Not a value trap, but not a screaming bargain either — a fairly-priced, high-yield office REIT.

7. Technicals (from the FMP tech block)

8. Moat & competitive position

BXP's moat is irreplaceable trophy assets in supply-constrained gateway CBDs — you cannot easily build another Prudential Center or a new tower in Midtown, and the "flight to quality" within office genuinely favors the best-in-class landlord (Q1'26 CBD portfolio 93.4% leased vs 87.4% total occupancy). That is a real, if narrow, advantage. But it is a moat around a structurally challenged, single asset class: hybrid work has permanently lowered office demand, and BXP has no diversification into the REIT sectors that are growing (industrial, data centers, residential). The competitive frame is other high-quality office/coastal REITs (Alexandria) and the broader "avoid office entirely" allocation decision.

Peer set (market cap, from FMP — note these are mixed REITs, not pure office comps): Alexandria Real Estate (ARE) $9.2B (closest — life-science office), Camden Property Trust (CPT, apartments) $11.8B, UDR (apartments) $13.4B, American Homes 4 Rent (AMH) $12.2B, Equity LifeStyle (ELS) $12.8B, Host Hotels (HST) $16.0B, Rexford Industrial (REXR) $7.9B, Omega Healthcare (OHI) $14.7B, Lamar (LAMR) $16.0B, AGNC (mortgage) $12.6B. BXP is the office name in a peer list dominated by faster-growing, less-cyclical property types — which is itself a tell about where capital would rather be.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): two quarters of occupancy decline; FFO guide cut below ~$6.50; interest coverage slipping toward ~1.5×; or a dividend reduction. Upgrade triggers: sustained occupancy gains + de-levering below ~7× + FFO re-accelerating.

11. Key risks

12. Verdict, position sizing & monitoring

Watch. BXP is a cheap-looking, high-quality office REIT — best-in-class trophy assets, a covered ~4% dividend, ~9.9× forward FFO, and a credible de-levering plan. But the top line has flatlined (~1%/yr), FFO is flat, the balance sheet carries 8.2× net-debt/EBITDA into an uncertain-rate world, and the asset class faces a real secular headwind. With no expert conviction in the Synthos KB, nothing pushes this from a fairly-valued income name to a buy. It is not a sell — the dividend is covered and the assets are real — but it does not clear the bar for fresh capital.


Provenance & disclosures